
GUTS Stock Forecast & Price Target
GUTS Analyst Ratings
Bulls say
Fractyl Health Inc. is positioned positively in the market due to the substantial rise in prescriptions for GLP-1 drugs, which increased by 587% from 2019 to 2024, indicating a growing recognition of their effectiveness in treating obesity and type 2 diabetes. The company’s advancements in GLP-1 PGTx therapy have demonstrated superior outcomes in blood glucose and weight control compared to existing treatments, supported by positive data from the REMAIN-1 trial. Furthermore, the anticipated scalability of manufacturing capabilities suggests that Fractyl Health is well-equipped to meet increasing demand as its product pipeline progresses.
Bears say
Fractyl Health Inc. faces a significant cash burn issue, compounded by the potential challenges in securing sufficient capital for the continued development of its Revita and Rejuva platforms. Additionally, while the company reports some improvements in metabolic parameters among participants, concerns remain regarding the effectiveness of its therapies in light of T2D patients' gradual loss of β-cell function and impaired GLP-1 function which may impede insulin production. Ultimately, the company’s reliance on milestone revenue from partnerships and collaborations raises further uncertainties about its financial stability and ability to advance its therapeutic offerings.
This aggregate rating is based on analysts' research of Fractyl Health Inc and is not a guaranteed prediction by Public.com or investment advice.
GUTS Analyst Forecast & Price Prediction
Start investing in GUTS
Order type
Buy in
Order amount
Est. shares
0 shares